Responses

Download PDFPDF

Letter
Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infection
Free
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses [https://authors.bmj.com/after-submitting/rapid-responses/].
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses [https://www.bmj.com/company/journals-terms-and-conditions-for-rapid-responses/] and understand that your personal data will be processed in accordance with those terms and our privacy notice [https://www.bmj.com/company/your-privacy/].
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

  • Published on:
    Guillain-Barre syndrome and other neurological complication in SARS-CoV-2: Role of antiganglioside antibodies and treatment option
    • Khichar Shubhakaran, Senior Professor and Head of Department of Neurology Dr. S.N. Medical College, Jodhpur, India

    I read an interesting case report of GBS with antiganglioside antibodies in SARS-CoV-2 by Civardi et al1. We are also seeing various complications like GBS, pseudotumorcerebri, precipitation of stroke, seizures etc2 but do not have the access to antiganglioside antibodies but, all those who can afford and get it done we should try for that and get it documented for academic and research purpose in this pandemic of modern time of advanced technology. We may screen for ganglioside antibodies to assess autoimmunity in Covid-19 patients3. The gangliosides are particularly abundant in the brain and in the nervous system; they participate in maintenance and repair of neuronal cells, memory formation and synaptic transmission4. So we have to be watchful in this regard towards impairment of these neurological functions i.e. new autoimmune disorder like GBS, multiple sclerosis(MS), neuromyelitis optica spectrum disorders(NMO-SD), chronic inflammatory demyelinating neuropathy(CIDP) etc. and precipitation of neurodegenerative and cognitive disorders in acute, convalescent ant post recovery follow up. Of course the paediatric population is less affected but as the gangliodides also take part in the development and regeneration of neurons the SARS-CoV-2 may affect the growth and development of paediatric population.
    As the intravenous immunoglobulins(IVIg) and plasmapharesis are useful in the treatment of GBS with antiganglioside antibodies the trial of IVIg, and monoclonal a...

    Show More
    Conflict of Interest:
    None declared.